Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment of Newly Diagnosed Patients with High-Risk APL By Ogkologos - September 3, 2025 466 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the APOLLO study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR The director’s cut: How Dr Catherine Elliott sees the future of... November 2, 2021 2020 National Cancer Opinion Survey: Cancer Screening and Mental Health During... October 1, 2020 What’s happened to cancer clinical trials during the COVID-19 pandemic? November 4, 2020 How I’m Working to Erase the Stigma of Lung Cancer: A... November 22, 2023 Load more HOT NEWS What the Budget 2021 means for research The Galleri multi-cancer blood test: what you need to know Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... Palbociclib Plus Endocrine Therapy Does Not Improve PFS over Capecitabine in...
